Compare Northern Trust Corporation Common Stock (NTRS) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northern Trust Corporation Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Northern Trust Corporation Common Stock trades at $162.48 (market cap $30.63B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Northern Trust Corporation Common Stock is far larger — about 2.9× Vaxcyte Inc. Common Stock's market cap, and Northern Trust Corporation Common Stock pays a 1.96% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northern Trust Corporation Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| NTRS | PCVX | |
|---|---|---|
Market Cap | $30.63B | $10.51B |
Volume | 964,550 | 2,644,694 |
Sector | Financials | Health |
52-Week High | $191.47 | $73.82 |
52-Week Low | $122.72 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | -$5.35B | $9.14B |
Dividend Yield | 1.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Northern Trust Corporation Common Stock
Northern Trust Corporation is a financial holding company that provides asset servicing, asset management, wealth management, and banking services through its Asset Servicing and Wealth Management segments. It serves corporations, institutions, and affluent individuals across US and international markets.
Read more on NTRS →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
